Henry C. Fung, MD

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

1. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.
   Clark JM, Kelley B, Titze J, Fung H, Maciejewski J, Nathan S, Rich E, Basu S, Kaufman HL.
   Oncology. 2013
   2013
   84(2):123-6. doi: 10.1159/000342764. Epub 2012 Dec 7.
   
2. CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1.
   Christopherson KW 2nd, Frank RR, Jagan S, Paganessi LA, Gregory SA, Fung HC.
   Exp Hematol. 2012
   2012 Nov
   40(11):945-52. doi: 10.1016/j.exphem.2012.07.009. Epub 2012 Jul 27.
   
3. Loss of CD26 protease activity in recipient mice during hematopoietic stem cell transplantation results in improved transplant efficiency.
   Yoo E, Paganessi LA, Alikhan WA, Paganessi EA, Hughes F, Fung HC, Rich E, Seong CM, Christopherson 2nd KW.
   Transfusion. 2012
   2012 Aug 6. doi: 10.1111/j.1537-2995.2012.03826.x. [Epub ahead of print]
   
4. A simplified technique for delivering total body irradiation (TBI) with improved dose homogeneity.
   Yao R, Bernard D, Turian J, Abrams RA, Sensakovic W, Fung HC, Chu JC.
   Med Phys. 2012
   2012 Apr
   39(4):2239-48. doi: 10.1118/1.3697526.
   
5. Cellular therapies supplement: strategies for improving transplant efficiency in the context of cellular therapeutics.
   Jimenez A, Fung HC, Christopherson KW 2nd.
   Transfusion. 2011
   2011 Nov
   51 Suppl 4:125S-137S. doi: 10.1111/j.1537-2995.2011.03375.x.
   
6. Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26(-)(/-) mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis
   Paganessi LA, Walker AL, Tan LL, Holmes I, Rich E, Fung HC, Christopherson KW 2nd
   Exp Hematol
   2011 Mar
   39(3):384-90
   
7. Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone, and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front-Line Therapy for Patients With Follicular or Marginal Zone Lymphoma.
   Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA.
   Clin Lymphoma Myeloma Leuk.
   2011 Jun 22
   
8. In vivo expansion of the megakaryocyte progenitor cell population in adult CD26-deficient mice
   Kidd S, Bueso-Ramos C, Jagan S, Paganessi LA, Boggio LN, Fung HC, Gregory SA, Christopherson KW 2nd
   Exp Hematol
   2011 Feb 1
   
9. Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26(-/-) mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis
   Paganessi LA, Walker AL, Tan LL, Holmes I, Rich E, Fung HC, Christopherson KW 2nd
   Exp Hematol
   2010 Dec 16
   
10. Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma - does it matter?
    Fung HC, Nathan S, Maciejewski JJ.
    Clin Pharmacol. 2010
    2010
    2:71-5. doi: 10.2147/CPAA.S6258. Epub 2010 Apr 14.
    
11. A case of myelodysplastic syndrome in a liver transplant patient
    Potru R, Ahn J, Fung H, Cohen SM
    Transplant Proc
    2009 Nov
    41(9):3947-8
    
12. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma
    Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ
    J Clin Oncol
    2008 Jan 1
    26(1):90-5
    
13. Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture
    Bakhshi T, Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganessi LA, Gregory SA, Fung HC, Christopherson KW 2nd
    Transfusion
    2008 Dec
    48(12):2638-44
    
14. Idiopathic hemophagocytic syndrome with a fulminant clinical course
    Khandelwal A, Shah NB, Eichenseer P, Welker M, Miller I, Nangia J, Farhat M, Gimelfarb A, Kassar M, Batus M, Gezer S, Shammo J, Gregory S, Fung H, Venugopal P
    Clin Adv Hematol Oncol
    2008 Aug
    6(8):587-90
    

• To watch a brief video of Henry C. Fung, MD, click the play button at the lower left corner of the video frame below.
• (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
• View Transcript

• Some of my patients commented that I’m funny, because I’m Doctor Fung: F-U-N-G. F-U-N is fun. And I like to tell stories. And I love to make jokes.

  We have a team of doctors that are national leaders, well-known investigators, and experts in the treatment of blood cancer and related disorders — and also experts in doing stem cell transplantations.

  Every patient has the right to know about their options. And we need to define their goals with them. It’s not a doctor deciding what the patient should do. They should be informed of all their options.

  I’m so proud that recently one of my patients invited me to go to his daughter’s graduation. He would never be able to go to her graduation without the transplant. And I’m very, very proud to be part of it.